3 min read
As European markets experience a boost from the prospect of lower U.S. borrowing costs, with indices like the STOXX Europe 600 Index rising, investors are increasingly focused on growth opportunities within the region. In this context, companies that combine robust growth potential with high insider ownership can be particularly appealing, as they often indicate strong internal confidence and alignment with shareholder interests.
|
Name |
Insider Ownership |
Earnings Growth |
|
Xbrane Biopharma (OM:XBRANE) |
21.8% |
57.5% |
|
Pharma Mar (BME:PHM) |
11.8% |
44.2% |
|
Marinomed Biotech (WBAG:MARI) |
29.7% |
20.2% |
|
KebNi (OM:KEBNI B) |
38.3% |
63.7% |
|
Elliptic Laboratories (OB:ELABS) |
24.4% |
80.6% |
|
CTT Systems (OM:CTT) |
17.5% |
37.9% |
|
Circus (XTRA:CA1) |
24.7% |
72.6% |
|
CD Projekt (WSE:CDR) |
29.7% |
39.5% |
|
Bonesupport Holding (OM:BONEX) |
10.4% |
63.2% |
|
Bergen Carbon Solutions (OB:BCS) |
12% |
64.6% |
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: PostNL N.V. offers postal and logistics services to businesses and consumers in the Netherlands, Europe, and internationally, with a market cap of €509.70 million.
Operations: The company generates revenue from its Parcels segment, amounting to €2.41 billion, and Mail in The Netherlands segment, contributing €1.32 billion.
Insider Ownership: 35.1%
PostNL is trading significantly below its estimated fair value, which suggests potential undervaluation. Despite a highly volatile share price recently, the company is expected to become profitable within three years, with earnings forecasted to grow 65% annually. However, revenue growth at 2.1% per year lags behind the Dutch market average of 7.1%, and interest payments are not well covered by earnings. Recent half-year results showed increased sales but a net loss of €41 million compared to last year.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training globally, with a market cap of SEK5.39 billion.
Operations: Surgical Science Sweden AB (publ) generates revenue through the development and marketing of virtual reality simulators designed for evidence-based medical training across Europe, the Americas, Asia, and other international markets.
